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Abstract  The  new  molecular  classiﬁcation  of  breast  cancers  deﬁnes  cancer  sub-groups  with
a distinct  prognosis  and  response  to  treatment.  Studies  on  the  literature  deal  with  the  imag-
ing of  each  tumour  sub-type.  The  radiologist  should  be  familiar  with  them  in  order  to  adapt
the care  of  an  aggressive  sub-type.  In  view  of  the  current  knowledge,  the  following  have  been
signiﬁcantly  more  often  observed:  mammographical  spiculated  mass  with  echogenic  halo  in
luminal A  sub-type;  architectural  distortion  in  luminal  B  sub-type;  an  irregular  mass  with  indis-
tinct margin  comprising  microcalciﬁcations,  with  an  abrupt  interface  in  the  sonography,  or
non-sonographic  mass  in  the  HER2  sub-type;  a  very  hypoechogenic,  lobulated  mass  with  indis-
tinct or  microlobulated  margin,  with  an  abrupt  interface,  sometimes  pseudo-benign,  in  the
triple-negative  sub-type.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
According  to  the  WHO,  the  histological  type  and  grade  of  the  tumour  are  indispensible
diagnostic  and  prognostic  morphological  elements  in  the  treatment  of  breast  cancer.  The
prognostic  and  predictive  elements  of  the  response  to  treatment  are  added  to  this,  that  is,
in  addition  to  the  histological  grade,  the  hormone  receptors  (oestrogen  (ER)  and  proges-
terone  (PR)  receptors)  and  the  HER2  status.  Since  2000,  the  breast  cancers,  in  particular
invasive  ductal  cancers,  have  been  reclassiﬁed  according  to  their  genomic  alterations  that
underlie  highly  different  prognoses.  This  is  the  molecular  or  ‘‘intrinsic’’  classiﬁcation  dis-
tinguishing  the  luminal  A,  luminal  B,  HER2  positive,  basal-like,  triple-negative  sub-types.
∗ Corresponding author.
E-mail address: m.boisserie-lacroix@bordeaux.unicancer.fr (M. Boisserie-Lacroix).
2211-5684/$ — see front matter © 2013 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
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Figure 1. 45 years old. Palpable mass. Grade III IDC. Sonogra-
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Genomic  tests,  determining  a  prognostic  signature,  have
een  developed  that  currently  do  not  ﬁnd  any  clinical
pplication  in  France.  However,  correlations  between  this
olecular  data  and  the  morphology,  grade  and  immuno-
istochemical  proﬁle  of  invasive  carcinomas  have  been
stablished.
The  authors  describe  the  radio-histological  aspects  of
nvasive  carcinomas  according  to  their  ‘‘traditional’’  histo-
rognostic  factors  and  then  describe  the  new  molecular
lassiﬁcation  that  the  radiologist  should  now  be  familiar
ith,  if  only  to  adapt  the  care  of  an  aggressive  tumoral  sub-
ype.  Recently,  papers  on  the  correlations  between  tumour
ub-type  and  conventional  imaging  have  been  published  on
 regular  basis.  The  studies  in  the  literature  are  retrospec-
ive,  the  methodology  differs,  they  are  sometimes  based
n  a  fairly  limited  number  of  cases  and,  above  all,  they  do
ot  necessarily  use  the  same  histochemical  criteria  for  the
lassiﬁcation  according  to  tumour  sub-type.
orrelations between imaging and
‘traditional’’ prognostic and predictive
actors
t  the  beginning  of  the  2000s,  several  authors  demonstrated
hat  factors  such  as  tumour  grade  and  hormone  receptors
oestrogens,  progesterone)  may  inﬂuence  the  appearance
n  the  imaging  [1,2].
he grade
rade  I  and  II  tumours,  with  a  fairly  slow  development,
resent  a  stroma  reaction  with  retraction  of  the  normal
arenchyma,  responsible  for  the  typical  appearance  of
alignancy  in  imaging.  In  Lamb’s  series,  in  the  mammog-
aphy,  spicules  were  observed  in  72%  of  the  grade  I  and
I  vs  24%  of  the  grade  III  [2]  and,  in  the  sonography,  a
eri-lesional  hyperechogenic  halo  and  a  posterior  shadowing
ere  observed  in  71%  of  the  grades  I  and  II.
Rapidly  evolving,  grade  III  cancers  do  not  develop  a
troma  reaction  and  display  a  round  shape.  In  Lamb’s  series,
n  the  sonography,  16%  of  them  presented  a  circumscribed
ontour  and  36%  a  posterior  enhancement  (vs  9%  of  the
rades  I  and  II)  [2].  Therefore,  in  2000,  Lamb  concluded
hat  the  grade  III  cancers  have  a  ‘‘paradoxically  benign’’
ppearance.  Recently,  Irshad  [3]  demonstrated  that  cancers
resenting  a  posterior  enhancement  have  a  24-time-higher
dds-ratio  of  being  grade  III  (95%  CI,  9.91—58.14;  P  <  0.01)
ompared  with  tumours  without  enhancement.  The  contri-
ution  of  the  colour  Doppler  should  be  taken  into  account:
istinct  vascularization  (not  quantiﬁed  in  the  studies)  in  the
olour  Doppler  is  also  associated  with  grade  III  [4]  (Fig.  1).
Grade  III  is  often  associated  with  other  factors  of  a
oor  prognosis.  Shin  [4]  showed  that  very  dense  masses
n  mammography,  with  a  circumscribed  or  microlobulated
ontour,  with  posterior  enhancement  in  the  sonography,  are
igniﬁcantly  observed  in  the  grade  III  cancers  presenting  a
egativity  of  the  hormone  receptors.
Recently,  Evans  correlated  the  mean  stiffness  as  mea-
ured  with  shear-wave  elastography  with  the  tumoral  grade.
rade  III  was  signiﬁcantly  associated  with  high  mean
a
a
c
thy: very hypoechogenic mass, oval, circumscribed margin, with
osterior enhancement, vascularised, ACR 4.
tiffness  (mean  value  Emed:  148  kPa).  The  difference  in
ardness  was  more  marked  between  grades  I  and  II  (85  and
39  kPa,  respectively)  than  between  grades  II  and  III  [5].  In
 series  of  337  invasive  cancers,  Chang  also  found  a  corre-
ation  between  the  high  tumour  grade  and  the  high  mean
alue  stiffness  [6].
he hormone receptors
he  presence  of  hormone  receptors  (R+  tumour)  is  a  good
rognosis  and  indicates  a hormone-sensitive  tumour.  Their
bsence  is  a less  favourable  prognosis.  R-  tumours  respond
etter  to  chemotherapy.
In  the  imaging,  R+  cancers  are  often  irregular  (80%)  and
ave  spiculated  margins  (68%),  signiﬁcantly  more  frequently
han  triple-negative  cancers  [7]  (Fig.  2). A  peripheral
chogenic  halo  is  noted  in  64%  of  the  R+HER—  cancers  [8].
ecently,  Irshad  [3]  demonstrated  that  cancers  presenting
 posterior  shadowing  have  an  odds-ratio  at  least  9  times
igher  of  having  a  hormone  receptivity  (95%  CI,  2.09—40.81;
 = 0.011)  compared  with  tumours  without  posterior  shadow-
ng  and  cancers  presenting  a  posterior  enhancement  have
n  odds-ratio  of  8  of  being  receptor-negative  for  oestro-
ens  and/or  progesterone  (95%  CI,  3.97—18.11;  P  <  0.001)
ompared  with  tumours  without  enhancement.
Recently,  Chang  carried  out  a  retrospective  study  on  the
ardness  of  invasive  cancers  in  elastography  by  correlat-
ng  the  status  of  the  receptors.  He  described  a signiﬁcant
ssociation  between  Emed  and  the  negativity  of  oestrogen
eceptors  (Emed  =  167  kPa  for  R—  cancers  and  138.7  kPa  for
+  cancers,  P  <  0.015).  The  correlation  was  not  signiﬁcant
or  the  progesterone  receptors  [6].
he HER2 status
he  over-expression  of  HER2  is  a factor  of  a  poor  prognosis,
 predictive  factor  of  a  response  to  anti-HER2  therapies,
nd  a  predictive  factor  of  resistance  to  tamoxifene  (by
rossing  between  routes  of  transduction  of  oestrogen  recep-
ors  and  HER2).  This  sub-type  of  cancer  beneﬁts  from
Correlation  between  imaging  and  prognostic  factors  
Figure 2. 67 years old. Discovery of a small irregular mass dur-
ing a screening mammography. Grade I IDC, ER = 90%. Sonography:
centimetric hypoechogenic mass with angular margins and high
intra-lesional elastographic value of 240 kPa.
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than  the  luminal  A  type.  Architectural  distortion  is  less  often
observed  in  luminal  B  (31%)  than  in  the  other  sub-types  [9].
However,  the  luminal  B  group  only  included  44  cases  in  this‘‘targeted’’  therapies,  treatments  directed  against  the  rel-
atively  speciﬁc  molecular  anomalies  of  cancer  cells,  in  this
case  molecules  targeting  the  family  of  HER2  receptors.
With  the  development  of  the  new  molecular  classiﬁ-
cation,  studies  have  been  carried  out  on  the  correlations
between  imaging  and  HER2  status. s
Figure 3. 54 years old. Screening examination. Grade I IDC, ER = 90
compression: stellate infra-centimetric mass ACR 5; b: sonography: hypo
c: elastography: Emed intra-lesional value of 70 kPa, peri-lesional value 229
he new molecular classiﬁcation
uminal type A
s  regards  to  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  the  tubular  carcinomas,  and  invasive  ductal
arcinomas  (IDC)  or  grade  I  or  II  invasive  lobular  carci-
omas  (ILC),  expressing  oestrogen  receptors  (R+),  with  a
ow  proliferation  index  (Ki67  <  15%,  interpreted  in  immuno-
istochemistry  technique).
In the  mammography,  in  Taneja’s  study,  the  spiculated
ass  is  signiﬁcantly  more  frequent  in  the  luminal  groups
42%)  than  in  the  other  sub-types  [9].  In  sonography,  all  the
riteria  of  malignancy  are  often  observed:  irregular  shape,
ngular  or  spiculated  margin,  echogenic  halo,  posterior
hadowing  [8]. The  tumour-parenchyma  interface  reveals
 desmoplastic  reaction  and  thereby  fairly  slow  growth
Fig.  3).
In  his  retrospective  study  on  the  hardness  of  invasive
ancers  in  elastography,  Chang  correlated  the  Emed  with
he  different  molecular  sub-types.  He  demonstrated  that
umours  with  an  Emed  <  50  kPa  were  luminal  sub-types  [6].
uminal B  type
s  regards  to  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  the  grade  II  or  III  invasive  carcinoma,  express-
ng  oestrogen  receptors  (R+),  with  Her2  Score  0,  1+,  2+  not
mpliﬁed  (luminal  B  HER2—)  or  ampliﬁed  (luminal  B  HER2+),
ith  a  high  index  of  proliferation  (KI67  >  15%).  Carcinomas
rising  with  BRCA  2  mutations  often  belong  to  this  molecular
ype.
In  Taneja’s  study,  the  spiculated  mass  was  signiﬁcantly
ore  often  observed  in  the  luminal  groups  than  the  other
ub-types.  They  less  often  belong  to  the  luminal  B  type  (33%)tudy.
%, PR = 70%, HER2—, Ki = 5%, luminal A: a: mammography, spot-
echogenic mass, with indistinct margin, and hyperechogenic halo;
higher at 180 kPa.
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In  the  sonography,  an  irregular  shape  (88%  of  the  cases)
nd  posterior  shadowing  (85%  of  the  cases)  was  signiﬁcantly
bserved  [8].  However,  the  examination  was  carried  out
ith  a  7.5  MHz  sound  and  the  authors  acknowledge  that  the
esults  would  certainly  have  been  different  with  more  recent
quipment  (Fig.  4).
he HER2 (non-luminal) type
s  regards  to  the  phenotype,  in  clinical  practice,  this  type
orresponds  to  the  grade  II  or  III  invasive  carcinomas,  not
xpressing  oestrogen  receptors  (R—),  with  Her2  Score  3+  or
+  in  FISH  ampliﬁed  immuno-histochemistry,  whatever  the
I67.
In  mammography,  the  mass  with  indistinct  margins  is  the
ost  common  mode  of  presentation:  42%  in  Taneja’s  series
9].  The  presence  of  calciﬁcations  (polymorphous,  in  the
ass  or  in  clusters  of  segmental  distribution)  is  signiﬁcantly
ssociated  with  an  HER2  +  status.  Their  presence,  correlated
ith  the  associated  intra-ductal  component,  may  predict  an
ER2+  status  when  the  HER2  score  equals  2+  on  the  micro-
iopsy  (in  immuno-histochemistry)  [4].
H
l
f
igure 4. 43 years old, self-palpation of a large right mass. Luminal B 
ocal hyperdensity; b: sonography: non-mass of 4 cm.
igure 5. 47 years old, palpable mass. IDC HER2+ (non-luminal). a: ma
ass with indistinct margin, presence of several polymorphous microcalcM.  Boisserie-Lacroix  et  al.
In  sonography,  a  rather  irregular  mass  is  observed.  The
argins  are  described  in  various  ways  in  the  literature.
owever,  the  assessment  of  the  margins  depends  on  the
pparatus  and  the  reading  by  the  technician:  signiﬁcantly
ndistinct  margins  in  94%  of  the  masses  for  Au-Yong  [8],
ut  spiculated  masses  in  56%  of  Wang’s  cases  [10]. The
umour-parenchyma  interface  is  more  often  abrupt  in  R-
ER2+  tumours  (91%)  than  in  the  R+HER2—  cancers  (64%)
8].  The  posterior  enhancement  is  more  often  observed
n  R—HER2+  cancers  (50%)  than  in  the  R—HER2—  cancers
29%)  in  Ko’s  study  [11].  Finally,  non-masses  are  most
ften  observed  in  the  HER2+  group:  32%  vs  16%  of  the
R  +  PR—HER2—,  perhaps  because  the  intra-ductal  compo-
ent  is  more  frequent  [4]  (Fig.  5).
In  Shin’s  study,  several  factors  have  been  grouped  to
btain  a  statistical  power.  In  this  way,  a  mass  with  indis-
inct  margins  is  signiﬁcantly  associated  with  a  high-grade,  a
—  status  and  HER2+  [4].
As  regards  to  the  elastrography,  in  Evans’  series,  enriched
ER2  tumours  have  a  higher  Emed  (160.3  ±  56.2  kPa)  than
uminal  tumours  (136.9  ±  57.2),  as  related  to  their  less
avourable  prognosis  [5].
IDC (HER2—). a: mammography, centred image: right supra-areolar
mmography, proﬁle (post-clip before neo-adjuvant chemotherapy):
iﬁcations; b: sonography: oval 20 mm mass with indistinct margin.
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Figure 6. 75 years old. Discovery of two hard masses during a medical examination. It consists of two triple-negative IDC. a: mammography:
 indistinct margin; b: sonography (upper quadrants): non-mass of mixed
rants). Round mass predominantly hyperechogenic.
(71  to  84%)  and  the  HER+tumours  (91%)  than  in  the  R+HER—
cancers  (64%)  [4,14—16]. Very  marked  hypoechogenicity  is
most  common:  48%  of  the  cases  in  Ko’s  series  [11].  The
echostructure  may  be  heterogeneous  with  zones  of  necro-
sis,  as  well  in  5  out  of  the  25  cases  of  tumours  over  3  cm  in
Kojima’s  study  [14]. Posterior  enhancement  is  observed  in
35.5%  to  49%  of  the  TN  cancers  and  50%  of  the  R—HER+  can-
cers  [12,14—16]  while  it  is  only  noted  in  29%  of  the  R+HER2—
cancers  in  Ko’s  study  [11].  This  corroborates  Shin’s  study:
posterior  enhancement  is  associated  with  the  high-grade
and  negativity  of  the  receptors  [4].  For  Dogan,  6  of  the  38
masses  (15.8%)  were  characteristic  of  a  solid  mass  of  benign
appearance  [15]  (Fig.  7).
Tamaki  recently  reviewed  the  characteristics  of  45  can-
cers  in  patients  presenting  a  mammography  classiﬁed  as
ACR1,  ﬁnding  that  the  majority  of  cancers,  in  sonography,
are  accompanied  by  an  oval  or  round  non-spiculated  mass
corresponding  to  a  TN  phenotype  and/or  grade  III  cancers
[17].
As  regards  to  the  elastography,  in  Evans’  series,  the  TN
tumours  had  the  highest  Emed  (169.1  ±  48.5  kPa).  The  hard-
ness  of  the  tissue  seemed  to  be  signiﬁcantly  correlated  with
the  tumoral  aggressiveness  [5].  Initially,  the  lowest  elasticityupper round mass with circumscribed margin, lower round mass with
hypo and hyperechogenic echostructure; c: sonography (lower quad
The basal-like type
In  clinical  practice,  this  type  corresponds  to  a  determined
histological  phenotype:  grade  III  IDC,  little  differentiated,
R—,  HER2—,  with  lymphocyte  inﬁltrate,  zones  of  tumoral
necrosis,  central  ﬁbrotic  zone,  and  ‘‘pushing’’  margins  (con-
tinuous  front  of  tumour  growth,  without  stroma  reaction).
It  is  a  heterogeneous  group  comprising  85%  of  the  BRCA1,
medullary  and  metaplastic  cancers.
In  the  mammography,  Taneja  observed  less  spiculated
masses  (13%)  and  more  masses  with  an  indistinct  margin
(47%)  than  in  the  luminal  and  HER2+  sub-groups  [9]. In  the
sonography,  the  halo  is  signiﬁcantly  less  frequent  (19%)  [8].
The triple-negative type
As  regards  to  the  phenotype,  in  clinical  practice,  this  triple-
negative  (TN)  sub-type  corresponds  to  grade  II  or  more  often
III  or  little  differentiated,  RE—,  HER2—  invasive  cancers.
This  is  the  sub-group  most  described  in  the  literature.
In  the  mammography,  the  mass  is  the  most  common  pre-
sentation,  round,  oval  or  lobulate  in  60  to  75%  of  the
cases,  with  a  circumscribed  margin  in  24%  to  43%  of  the
cases,  attesting  to  its  fast  growth  [12—16]  (Fig.  6).  Ko
[11]  found  a  signiﬁcant  difference  between  TN  and  control
groups  (ER+PR—HER—  and  ER+PR—HER+)  for  microcalciﬁ-
cations  (less  frequent  since  the  TN  tumour  does  not  go
through  a  pre-cancerous  phase)  and  focal  asymmetries  in
density  (more  frequent  in  the  TN).  However,  the  frequency
of  the  microcalciﬁcations  in  this  sub-type  is  in  various  ways
assessed  in  the  literature:  11/105  cases  (12%)  of  TN  and
16/105  cases  (16.8%)  of  the  control  group  R+HER2—  in  the
series  by  Boisserie-Lacroix  et  al.  [12].
The  rate  of  normal  mammographies  also  varies  according
to  the  series  (from  0  to  18%)  [12—16].  The  negativity  of  the
mammography  may  be  due  to  the  ‘‘masking  effect’’  of  the
breast  density  that  reduces  the  contrast,  and  by  the  rapid
progression  of  these  tumours  that  are  not  accompanied  by
architectural  disorganisation.In  the  sonography,  the  predominance  of  the  round-
oval-lobulate  mass  is  found  in  65.1%  to  70%  [12—16],
with  an  indistinct  or  microlobulated  margin.  The  tumour-
parenchyma  interface  is  most  often  abrupt  in  TN  tumours
Figure 7. 42 years old. Discovery of a palpable mass during a
gynaecological examination. Triple-negative IDC. Sonography: oval
2 cm mass with microlobulated margin.
2 M.  Boisserie-Lacroix  et  al.
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pseudo-benign,  with  a  high  mean  stiffness  value  in  the
triple-negative  sub-type.
TAKE-HOME  MESSAGES
General  ideas
• Breast  cancers  are  classiﬁed  into  tumour  sub-types
according  to  their  molecular  characteristics.
• Immuno-histochemical  results  are  used  in  clinical
practice.
• Studies  are  published  on  a  regular  basis  on  the
imaging  aspects  as  a  function  of  this  new  molecular
classiﬁcation.
Main  results:  statistically  signiﬁcant  associations
• Very  dense  mass  with  a  circumscribed
or  microlobulated  contour,  with  posterior
enhancement,  and  grade  III  R—.
• Spiculated  mass  and  luminal  sub-type.
• Calciﬁcations  and  HER2+  sub-type.
• Round-lobular  mass  with  very  hypoechogenic
microlobulated  margin  with  abrupt  interface  and  TN
sub-type.
Case report
36  years  old.  Mass  discovered  by  self-palpation,  at  the  union
of  the  left  outer  quadrants,  of  2  cm.  No  palpable  axillary
adenomegaly.  Family  antecedents  in  the  mother  at  the  age
of  55.  A  sonography  image  is  provided  (Fig.  8).
Questions
1.  How  do  you  describe  this  mass  in  your  report?
2.  Do  you  classify  this  mass:  BI-RADS  ACR  3?  ACR  4?  ACR  5?
3.  Worried  because  of  the  1st  degree  family  antecedent,
the  young  patient  requested  surgical  excision,  but  in32  
as  expected  in  the  TN  cancers  and  the  highest  in  the  low-
rade  luminal  cancers  that  develop  a  desmoplastic  reaction.
n  fact,  the  hardness  of  tissue  involves  complex  mechanisms
nd  combines  tumour  cellularity,  density  in  microvessels,
ecrosis,  ﬁbrosis,  etc.
he apocrine type
he  more  recent  individualization  is  still  incomplete.
linical implications for therapy
reast  cancer  has  become  a  heterogeneous  disease  with
linically  pertinent  sub-groups  with  their  own  prognostic
mpact.  In  imaging,  beyond  the  characterization  of  a  mass
nd  its  classiﬁcation  according  to  the  BI-RADS  category  by
he  ACR,  it  is  important,  as  of  the  ﬁrst  mammo-sonography,
o  be  familiar  with  the  predictive  characteristics  of  an
ggressive  tumoral  sub-type  in  order  to  organise  the  care  as
oon  as  possible  for  the  patient.  In  particular,  the  TN  type  is
apidly  evolving,  of  greater  tumoral  size,  in  young  women,
nd  should  not  be  mistaken  by  the  radiologist  for  a  benign
umour.
With  invasive  breast  cancer,  the  indication  for  adjuvant
hemotherapy  is  based  on  the  analysis  of  the  ‘‘traditional’’
linical  and  histoprognostic  factors,  and  is  decided  on  during
he  multi-disciplinary  meeting  on  the  recommendations  of
onsensus  recommendations  (St-Gallen,  St-Paul-de-Vence,
tc.)  aided  by  the  use  of  adjuvant  online  software.  In  paral-
el,  over  the  last  decade,  the  expression  proﬁles  have  helped
eﬁne  tumours  with  a  different  prognosis,  opening  the  way
o  therapeutic  strategies  adapted  to  the  tumour  proﬁle,  and
ven  to  a  prediction  of  the  response  or  lack  of  response  to
hemotherapy.  For  example,  in  patients  with  a  good  prog-
osis,  without  lymph  node  invasion  or  with  R+  and  grade  II
umour  (luminal  A  and  B),  the  high  genome  grade  (genes
ssociated  with  the  proliferation  and  regulation  of  the  cell
ycle,  high  Ki67)  and  the  low  genome  grade  now  allow  for
he  acceptance  or  rejection  of  chemotherapy.
Three  genome  analysis  tests  have  been  marketed.  The
rice  is  high  and  not  reimbursed  by  the  national  health.
n  France,  they  are  not  considered  to  be  useable.  Ther-
peutic  trials  are  in  progress  (ex.  MINDACT  based  on  the
‘70-gene  signature’’,  Mammaprint)  to  validate  the  feasibil-
ty  of  genome  analysis  in  everyday  practice.
onclusion
n  view  of  current  knowledge,  the  most  frequent  signiﬁcant
spects  are:
stellar  mammography  mass  —  irregular  mass  with
echogenic  halo,  in  the  luminal  A  sub-type;
architectural  distortion  in  the  luminal  B  sub-type;
irregular  mammographic  mass  with  indistinct  margin  com-
prising  microcalciﬁcations,  with  abrupt  interface  in  the
sonography  or  non-echographic  mass  in  the  HER2  sub-
type;
lobular  mass  with  an  indistinct  or  microlobulated  margin,
very  hypoechogenic,  with  abrupt  interface,  sometimes
Figure 8. Sonography: oval mass, with microlobulated margin,
very marked hypoechogenicity, with posterior enhancement, not
strictly parallel. ACR 4.
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[Correlation  between  imaging  and  prognostic  factors  
2  months  due  to  professional  problems.  What  is  your
response?
4.  Does  this  mass  initially  suggest:  an  adenoﬁbroma/a  phyl-
lode  tumour/an  HER2+  cancer/a  triple-negative  cancer?
Answers
1.  It  consists  of  an  oval  mass,  with  a  microlobulated  margin,
very  hypoechogenic,  with  posterior  enhancement.
2.  The  microlobulated  margin,  the  very  marked  hypoe-
chogenicity  and  the  great  axis  that  is  not  strictly  parallel
does  not  indicate  ACR  3  classiﬁcation  but  ACR  4.
3.  The  appearance  is  suspect,  and  suggests  a  high-grade
malignant  tumour  due  to  the  pseudo-benign  characteris-
tics,  requiring  quick  treatment.
4.  The  sonography  suggests  a  malignant  triple-negative
tumour.  The  core  biopsy  14  G  concludes  as  to  invasive
grade  III  ductal  carcinoma,  ER  PR  =  0%,  HER2—.
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